Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$122.22

5.97 (5.14%)

, ZGNX

Zogenix

$43.05

1.59 (3.84%)

14:25
10/15/19
10/15
14:25
10/15/19
14:25

Piper Jaffray healthcare analyst to hold an analyst/industry conference call

Healthcare Analysts, along with a KOL pediatric epilepsy expert, discuss the evolving therapeutic landscape for epilepsy, focusing on Epidiolex (GWPH) and the current prescribing dynamics and future expectations, as well as the potential role for Fintepla (ZGNX) and outcome expectations for the ongoing pivotal LGS trial on an Analyst/Industry conference call to be held on October 15 at 3 pm.

GWPH

GW Pharmaceuticals

$122.22

5.97 (5.14%)

ZGNX

Zogenix

$43.05

1.59 (3.84%)

  • 15

    Oct

  • 05

    Nov

GWPH GW Pharmaceuticals
$122.22

5.97 (5.14%)

09/19/19
HCWC
09/19/19
NO CHANGE
Target $23
HCWC
Buy
Zynerba selloff on open-label data for Zygel 'unwarranted,' says H.C. Wainwright
After Zynerba (ZYNE) announced yesterday top line results from the open label Phase 2 clinical trial that assessed the safety and efficacy of Zygel in developmental and epileptic encephalopathies, or DEE, H.C. Wainwright analyst Oren Livnat said the shares have been "punished," which he sees as "unwarranted" since he views the data as encouraging. Investors, comparing Zygel head-to-head with GW Pharma's (GWPH) Epidiolex, appear to be concluding that Zygel looks less efficacious, which he doesn't think is necessarily the case. Furthermore, this line of "reasoning entirely misses the point of this study," which were identifying an efficacy signal and confirming Zygel's likely superior safety profile vs Epidiolex, both of which he thinks Zynerba achieved. Livnat reiterated a Buy rating on Zynerba shares.
09/27/19
OPCO
09/27/19
NO CHANGE
Target $233
OPCO
Outperform
GW Pharmaceuticals price target lowered to $233 from $239 at Oppenheimer
Oppenheimer analyst Esther Rajavelu reiterated an Outperform rating on GW Pharmaceuticals and lowered her price target to $233 from $239 given that the company is several months into its U.S. Epidiolex launch. In a research note to investors, Rajavelu says she believes Epidiolex U.S. uptake continues to progress well, and awaits management comments on its EU pricing and commercial strategy.
10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.
10/14/19
LEER
10/14/19
NO CHANGE
LEER
Outperform
Investor concerns related to GW Pharmaceuticals 'misplaced,' says SVB Leerink
SVB Leerink analyst Marc Goodman notes that it has been a "tough late summer/fall" for GW Pharmaceuticals, as misplaced investor concerns have beaten up the stock significantly and Friday was no different. The analyst points out that the concern on Friday started as investors checked on the weekly Symphony Rx data for the first week of October, which indicated a significant decline from the previous week. He was able to confirm with the company that a "very significant specialty pharmacy" had stopped reporting weekly Rxs to the data providers that flow into Symphony Rx, which makes sense given the surprisingly abrupt Rx trend on Friday. Goodman still believes Epidiolex can be a "significant" product in epilepsy. He reiterates an Outperform rating on the shares.
ZGNX Zogenix
$43.05

1.59 (3.84%)

06/27/19
GUGG
06/27/19
UPGRADE
GUGG
Buy
Zogenix upgraded to Buy from Neutral at Guggenheim
06/27/19
06/27/19
UPGRADE
Target $64

Buy
Zogenix upgraded to Buy Fintepla NDA news at Guggenheim
As previously reported, Guggenheim analyst Yatin Suneja upgraded Zogenix to Buy from Neutral after speaking with management following the news on Fintepla NDA resubmission in Dravet in Q3. The analyst believes the company has a clear understanding with the FDA on potential approval pathway and views the news as the best case scenario. The company also announced the loss of breakthrough designation, which is surprising but in line with FDA policy, he notes, adding however, that it does not change his view on the approvability of the drug and thinks priority review could help with a speedy approval. Suneja also raised his price target on the shares to $64 from $40.
06/28/19
MZHO
06/28/19
NO CHANGE
Target $65
MZHO
Buy
Zogenix price target raised to $65 from $58 at Mizuho
Mizuho analyst Difei Yang raised her price target for Zogenix to $65 from $58 following the FDA's decision to allow a re-submission of the new drug application for Fintepla. The analyst believes a priority review is highly likely and views the FDA's decision as a positive. She reiterates a Buy rating on Zogenix shares.
08/26/19
PIPR
08/26/19
NO CHANGE
PIPR
Overweight
Zogenix should be bought on weakness from Modis deal, says Piper Jaffray
Piper Jaffray analyst Danielle Brill recommends buying shares of Zogenix on weakness following the company's acquisition of Modis Therapeutics. While pipeline diversification makes sense, investors are likely thrown off by the timing of the deal, given the proximity to Fintepla approval, Brill tells investors in a research note. Also, a potential near-term takeover of Zogenix now seems unlikely, adds the analyst. However, she still thinks Fintepla will be a commercial success. Brill expects Zogenix shares to recover after the new drug application filing is accepted and she keeps an Overweight rating on the name with a $64 price target. The stock in afternoon trading is down 13%, or $6.68, to $43.33.

TODAY'S FREE FLY STORIES

11:37
10/23/19
10/23
11:37
10/23/19
11:37
General news
2-Yr FRN Note Auction Bid/Cover data reported »

2-Yr FRN Note Auction…

11:37
10/23/19
10/23
11:37
10/23/19
11:37
General news
2-Yr FRN Note Auction Total Amount data reported »

2-Yr FRN Note Auction…

SAVE

Spirit Airlines

$37.33

0.08 (0.21%)

, EADSY

Airbus

$0.00

(0.00%)

11:33
10/23/19
10/23
11:33
10/23/19
11:33
Periodicals
Spirit Airlines near deal for as many as 100 Airbus A320 jets, Reuters says »

Spirit Airlines (SAVE) is…

SAVE

Spirit Airlines

$37.33

0.08 (0.21%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 13

    Nov

KAMN

Kaman

$58.38

-0.2 (-0.34%)

11:33
10/23/19
10/23
11:33
10/23/19
11:33
Hot Stocks
Kaman executes long term agreement with Winglet Technology »

Kaman Composites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

TWTR

Twitter

$38.93

0.11 (0.28%)

11:32
10/23/19
10/23
11:32
10/23/19
11:32
Earnings
Fly Intel: What to watch in Twitter earnings report »

Twitter (TWTR) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

ABMD

Abiomed

$175.20

4.45 (2.61%)

, ABT

Abbott

$81.49

0.95 (1.18%)

11:29
10/23/19
10/23
11:29
10/23/19
11:29
Recommendations
Trial for potential Abiomed competition pushed back a year, says Piper Jaffray »

This morning, the primary…

ABMD

Abiomed

$175.20

4.45 (2.61%)

ABT

Abbott

$81.49

0.95 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 13

    Nov

HEMA

HemaCare Corp.

$0.00

(0.00%)

11:27
10/23/19
10/23
11:27
10/23/19
11:27
Periodicals
Breaking Periodicals news story on HemaCare Corp. »

HemaCare Corp. working…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$175.20

4.45 (2.61%)

, ABT

Abbott

$81.52

0.98 (1.22%)

11:27
10/23/19
10/23
11:27
10/23/19
11:27
Hot Stocks
Abiomed jumps after Abbott heart pump trial pushed back one year »

An update today on…

ABMD

Abiomed

$175.20

4.45 (2.61%)

ABT

Abbott

$81.52

0.98 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 13

    Nov

MGNX

MacroGenics

$9.87

-1.17 (-10.60%)

, ZYME

Zymeworks

$30.25

-0.26 (-0.85%)

11:26
10/23/19
10/23
11:26
10/23/19
11:26
Recommendations
MacroGenics, Zymeworks analyst commentary  »

MacroGenics price target…

MGNX

MacroGenics

$9.87

-1.17 (-10.60%)

ZYME

Zymeworks

$30.25

-0.26 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 06

    Nov

TRU

TransUnion

$82.71

2.31 (2.87%)

11:26
10/23/19
10/23
11:26
10/23/19
11:26
Conference/Events
TransUnion management to meet with SunTrust »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 19

    Nov

CVM

CEL-SCI

$7.35

(0.00%)

11:25
10/23/19
10/23
11:25
10/23/19
11:25
Options
Cel Sci call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCG

NRC Group

$13.00

(0.00%)

, ECOL

US Ecology

$66.75

0.245 (0.37%)

11:25
10/23/19
10/23
11:25
10/23/19
11:25
Conference/Events
US Ecology to host special shareholder meeting »

Special Shareholder…

NRCG

NRC Group

$13.00

(0.00%)

ECOL

US Ecology

$66.75

0.245 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 31

    Oct

SNAP

Snap

$13.24

-0.76 (-5.43%)

11:19
10/23/19
10/23
11:19
10/23/19
11:19
Hot Stocks
Snap says DOJ, SEC no longer pursuing investigations of IPO disclosures »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
10/23/19
10/23
11:17
10/23/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
10/23/19
10/23
11:16
10/23/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$184.34

2.07 (1.14%)

11:05
10/23/19
10/23
11:05
10/23/19
11:05
Hot Stocks
Facebook shares up 1.6% as CEO testifies on Capitol Hill »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

CNC

Centene

$48.49

-0.28 (-0.57%)

11:05
10/23/19
10/23
11:05
10/23/19
11:05
Options
Centene call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

D

Dominion

$83.07

0.29 (0.35%)

11:03
10/23/19
10/23
11:03
10/23/19
11:03
Hot Stocks
Dominion, Smithfield Foods double investment in renewable natural gas to $500M »

Dominion Energy and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

BA

Boeing

$345.52

8.07 (2.39%)

11:02
10/23/19
10/23
11:02
10/23/19
11:02
Hot Stocks
Boeing CFO says it will take 'several quarters' to deliver parked 737 MAX jets »

CFO Greg Smith says it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BA

Boeing

$345.79

8.34 (2.47%)

11:00
10/23/19
10/23
11:00
10/23/19
11:00
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing says studying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

MMM

3M

$166.93

-0.63 (-0.38%)

10:55
10/23/19
10/23
10:55
10/23/19
10:55
Options
3M put volume heavy and directionally bearish »

Bearish flow noted in 3M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GLOG

GasLog

$14.29

0.325 (2.33%)

, GLOP

GasLog Partners

$20.24

0.35 (1.76%)

10:55
10/23/19
10/23
10:55
10/23/19
10:55
Conference/Events
Deutsche Bank shipping analyst to hold analyst/industry conference call »

Analysts, along with…

GLOG

GasLog

$14.29

0.325 (2.33%)

GLOP

GasLog Partners

$20.24

0.35 (1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 30

    Oct

  • 06

    Nov

BA

Boeing

$346.26

8.81 (2.61%)

10:54
10/23/19
10/23
10:54
10/23/19
10:54
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing CEO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BA

Boeing

$346.90

9.45 (2.80%)

10:53
10/23/19
10/23
10:53
10/23/19
10:53
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing sees first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FCX

Freeport McMoRan

$9.98

0.06 (0.60%)

10:51
10/23/19
10/23
10:51
10/23/19
10:51
Hot Stocks
Freeport McMoRan says current copper prices not sustainable »

Management said the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.